Trial Profile
Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors CerRx
- 22 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 22 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2021.
- 16 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.